Issue link: https://www.e-digitaleditions.com/i/1529207
14 BioPharm International ® Manufacturing and Facilities eBook November 2024 www.biopharminternational.com G lobal spending on pharmaceuticals and biotech therapies is forecast to reach US$2.3 trillion by 2028 amid growing de- mand and an aging population (1). In re- sponse, the life sciences industry is partnering with contract development and manufacturing organi- zations (CDMOs) to meet this challenge. To deliver potentially life-changing therapies to patients faster, biopharma companies are leveraging CDMOs' capabilities to rapidly expand manufactur- ing capacity, utilizing novel modular and replication strategies. The industry is also drawing on CDMOs' ability to leverage their regulatory landscape exper- tise to ensure that lifesaving therapies are delivered to the patient on time and on budget. Growth in the CDMO sector Biopharma companies partner with CDMOs to han- d le com mercia l izat ion, enabl i ng t he biopha r ma companies to efficiently manage their pipelines and focus on their core priorities, namely innovating new medicines. In response to growing outsourcing demand from biopharma companies, the CDMO sec- tor is also growing. Since 2020, industry estimates point to a 20% increase globally in the number of CDMO facilities that are manufacturing clinical- or commercial-scale biologics (2). To provide greater manufacturing capacit y in a growth environment, the increase in new facilities is set to continue. As CDMOs look to deliver new fa- cilities in diverse geographical locations in a fast, risk-f ree manner, cut ting-edge technolog y, com- bined with innovative execution strategies, can play a central role in realizing these ambitions. The modular mindset Indust r y best prac t ice i n CDMO projec t del iver y centers on digital replication and cloning. The use of digital tools and standardized platforms allows CDMOs to realize the f ull potential of the "design How Modularization and Digital Delivery are Transforming Pharma Manufacturing Jordan Ulrich is vice president, Project Delivery, FUJIFILM Diosynth Biotechnologies, and Dana Tilley is vice president and general manager, Life Sciences North America, Jacobs. Modular and replication strategies are being utilized to meet growing demand for CDMO facilities. KUGELWOLF - STOCK.ADOBE.COM